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Portal vein tumor thrombosis (PVTT) is a common complication of hepatocellular carcinoma (HCC) and has a negative impact on
prognosis.his characteristic feature led to the rationale of the present trial designed to assess the eicacy and the safety of yttrium-
90 glass-microsphere treatment for advanced-stage lobar HCCwith ipsilateral PVTT. 18 patients with unresectable lobar HCC and
ipsilateral PVTT were treated in our institution with 90Y-microS radioembolization. Patients were evaluated every 3 to 6 months
for response, survival, and toxicity. Mean follow-up was 13.0 months (2.2–50.6). Outcomes were: complete response (� = 2), partial
response (� = 13), stable disease (� = 1), and progressive disease (� = 2) giving a disease control rate of 88.9%. Four patients were
downstaged. Treating lobar hepatocellular carcinoma with ipsilateral portal vein thrombosis with yttrium-90 glass-microsphere
radioembolization is safe and eicacious. Further clinical trials are warranted to conirm these results and to compare 90Y-microS
with sorafenib, taking into account not only survival but also the possibility of secondary surgery for putative curative intention
ater downstaging.
1. Introduction
Hepatocellular carcinoma (HCC) is a common cancer with
an estimated annual incidence of 600,000 worldwide [1].
During the disease course, 40% of patients will develop portal
vein tumor thrombosis (PVTT) [2, 3], a hallmark of advanced
disease recognized as a poor prognosis factor by most
classiication systems: Barcelona Clinic Liver Cancer (BCLC)
[4] and Cancer Liver Italian Program (CLIP) [5]. Patients
with PVTT involving the portal trunk or main branch are
considered to have advanced-stage disease (BCLC class C),
independently of liver function or tumor size. Because of the
risk of hepatic ischemia, the presence of PVTT complicates,
or even contraindicates, locoregional treatments such as
transarterial embolization/chemoembolization (TAE/TACE)
designed to block arterial blood low [6, 7]. For these patients
with advanced-stage HCC, palliative systemic treatments
may be proposed [8]: sorafenib is currently the gold standard,
even if debated, allowing signiicant improvement in time to
progression and survival [9].
Considering the arterial hypervascularization associated
with PVTT [10] and the radiosensitivity of HCC [11], radioi-
sotopes would be a logical therapeutic option.
Recent retrospective analyses of single-center series have
demonstrated an acceptable safety proile for new modalities
of selective internal radiation therapy (SIRT) using radiola-
beled glass microspheres, even in the presence of PVTT [12–
18].
90Y-microspheres radioembolization is a recent concept
in radiation therapy for HCC. Radiolabeled particles injected
into the hepatic artery become trapped at the precapillary
level where they emit potentially lethal internal radiation.
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his selective mechanism limits exposure to the surrounding
normal parenchyma, thereby permitting higher dose delivery
than with an external beam [14, 18].
We report here our experience with 18 patients with lobar
HCC and ipsilateral intrahepatic PVTT given SIRT using
yttrium-90 glass microspheres (90Y-microS). hese patients
showing advanced diseases (PVTT) but involving only one
lobe were treated with the intention to downstage their
disease to a curative surgical treatment (transplantation or
resection).
2. Materials and Methods
2.1. Patients and Tumors. From January 2007 to Decem-
ber 2010, 63 patients were treated in our center for HCC
using intra-arterial 90Y-microS injections. Eighteen of these
patients had lobar HCC with intrahepatic ipsilateral PVTT.
All 18 patients had preserved hepatic function (<2.5XULN
total bilirubine, <5XULN aminotransferases) and were in
good general condition (WHO performance status score 0 or
1).
his retrospective study group included twelve men and
six women, mean age 64.4 years, age range 44–77 years
(Table 1). Histological and radiographic diagnoses were
established in 16 patients, radiographic diagnosis alone in two
[19]. No attempt was made to obtain a biopsy of the portal
thrombus prior to treatment, but triphasic helical computed
tomography demonstrated contrast uptake kinetics charac-
teristic of PVTT observed in HCC: arterial enhancement
and portal washout. he pathology classiication was severe
ibrosis in two patients; the other 16 had cirrhosis. he
main underlying etiology was alcohol (� = 10). All tumors
were unilobular with 7 showing multifocal and 3 iniltrating
patterns.hePVTTwas ipsilateral in all cases, branch throm-
bosis in 10, and intrahepatic trunk thrombosis in 8, extending
to lobular or segmental branches in 3 patients and to a
hepatic vein in one. Serum alpha-fetoprotein level was below
400 ng/mL (parameter of the CLIP classiication) in fourteen
patients (normal in six), elevated in four (>400 ng/mL). For
13 patients, this protocol was the irst-line treatment. Five
patients had had one or more previous treatments: TACE
(� = 3), sorafenib (� = 2), and radiofrequency (� = 2).
Treatment with sorafenib was stopped at least one month
before the SIRT procedure. One patient was treated with
sorafenib during the procedure.
his retrospective study was approved by the institutional
ethic board.
2.2. Treatment Planning. Pretreatment angiography and
technetium-99 macroaggregated albumin single-photon
emission computed tomography with CT coregistration
(MAA SPECT/CT) were performed to assess gastrointestinal
low and lung shunting [20]. A glass-based device (heraSp-
here, Ottawa, Canada) was used. he treatment by 90Y
glass microspheres was carried out as described by Salem
and hurston [21]. he activity to be injected (� inj) was
classically calculated with the aim of delivering a dose � of
120 ± 20 Gy to the volume to be treated (i.e., the injected liver,
usually one lobe). his dose was calculated according to the
Table 1: Baseline characteristics (� = 18).
Characteristic Value
Mean/median age (range) (y) 64.4/63.0 (44–77)
Sex ratio M/F (�) 12/6
Cirrhosis/ibrosis (�) 16/2
Main etiology (�):
Alcohol/HCV/haemochromatosis/
dysmetabolic syndrome
10/4/3/1
Child-Pugh score (�): A5-6/B7 13/5
CLIP score (�): 2/3/4 11/5/2
Distribution (�):
unifocal/multifocal/iniltrating
8/7/3
Mean/median (range) size (cm) 8/8.75 (3–13)
Portal vein tumour thrombosis (�):
Branch 10 (8 right/2 let)
Trunk (or trunk + branch) 8
Tumour location (�): right/let 12/6
Mean/median (range): alpha-fetoprotein
(ng/mL)
7932/36.5 (3–91000)
following formula, based on the Medical Internal Radiation
Dose (MIRD) formalism, previously described and widely
used [12, 16, 21, 22]:
�(Gy) = � inj(GBq) ⋅ (1 − �) ⋅ 50/�(Kg), (1)
where “�” is the lung shunt fraction, and “�” is the weight of
the injected liver.
2.3. Dosimetric Approach. SPECT acquisitions parameters
were as follows: 32 projections, 180∘, 128∗128, 30 s/projection
(Symbia T2 gantry, Siemens, Germany). SPECT data were
reconstructed using an iterative method (OSEM, 5 iterations,
8 subsets) with attenuation and scatter correction and then
visualized with or without fusion with CT scan data.
he SPECT/CT quantitative uptake analysis of tumoral
and nontumoral liver tissue was performed using the “vol-
umetric analysis” sotware (Syngo workstation, Siemens).
Briely, this sotware allowed us to generate semiautomat-
ically volume of interest (VOI) in the liver and tumor by
means of an isocontour deinitionmethod. For each VOI, the
threshold value was adjusted so that the isocontour of the
distribution volume ofMAAwas superimposed on the fusion
images that corresponded to the contours of the liver and
tumor. hese VOIs were then used to calculate the volumes
of the liver and the tumor (expressed in mL) in addition to
the total activity (expressed in counts) contained in the liver
(CPL) and tumor (CPtum). Volume and total counts in the
healthy liver (CPHL) were calculated by substracting liver and
tumor parameters.
he dose absorbed in the tumour and in the healthy liver
were then calculated using the classical formula:
�(Gy) = � (GBq) ⋅ 50/�(Kg), using:
(i) the activity � tum contained in the tumor (� tum =
� inj(GBq) ⋅ (1 − �) ⋅ CPtum/(CPtum + CPHL)) and its
weight for the tumoral dose;
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(ii) the activity�HL contained in the healthy liver (�HL =
� inj(GBq) ⋅(1−�)⋅CPHL/(CPHL+CPtum)) and its weight
for the healthy liver dose.
2.4. Treatment Procedure. Within 2 weeks of the planning
angiography study, the prescribed activity of 90Y glass micro-
spheres was administered by placing the tip of the delivery
catheter in the same anatomic position as that used for the
99mTc-MAA injection. Administration of 90Y glass micro-
spheres was always done selectively, in a lobar or segmental
manner. Bremsstrahlung imaging was performed to conirm
pretreatment MAA SPECT data for tumor targeting.
2.5. Evaluation and Followup. Clinical and biological evalua-
tions were done ater 1 and 4 weeks and then every 3 months.
Analysis of eicacy was done at 3 and 6 months and then
every 3 to 6 months by assessing European Association for
the Study of the Liver (EASL) response criteria [19]: complete
response (CR): absence of any enhancing tissue; partial
response (PR): >50% decrease in enhancing tissue; stable
disease (SD): <50% decrease in enhancing tissue. Progressive
disease (PD) was deined as any increase in enhancement
of the treated tumor that clinically would translate into
additional locoregional therapy (i.e., repeat 90Y). Safety was
assessed according to the Common Terminology Criteria for
Adverse Events CTCAEv3.0 criteria [23]. Pathologic analysis
of resected specimens in secondly operated patients was
performed.
2.6. Statistics. he database was closed on October 1, 2011,
the date at which all data were censored. Progression-free
survival (PFS) was measured from the date of the irst
treatment until the date of progression in the treated liver.
Overall survival (OS) was measured from the date of the
irst treatment until the date of death from any cause or of
last followup. SAS sotware was used to determine overall
survival and progression-free survival using the Kaplan-
Meier method. he Kruskal-Wallis test was used to look
for diferences between controlled and noncontrolled tumors
and univariate analysis applied the chi-square test with � <
0.05 considered as statistically signiicant.
3. Results and Discussion
3.1. Patients and Treatments. he 18 patients received 21 treat-
ments. hree patients received a second dose either because
the irst dosimetry was insuicient (� = 2; 101 and 106Gy,
resp.) or because of an insuicient target (� = 1 multifocal
tumor with 2 feeding arteries). Treatments characteristics are
shown in Table 2.
he pulmonary shunt, determined by monitoring albu-
min macroaggregates, was minimal (mean 6.0%, median
2.45%, range 0–43.5%) except in one patient (43.5% in a
patient with a voluminous intratumor arterioportal shunt).
Injected activity varied from 1.31 to 7.51 GBq (median
2.45GBq). he lowest activity (1.31 GBq) was delivered for
the patient with the intratumor shunt in order to hold lung
exposure below 30Gy (estimated 28.5Gy). he median dose
delivered to the target volume was 117.8 Gy, approaching the
aim of 120 ± 20Gy [12, 16, 21, 22]. Two patients received an
intensiication of the treatment (increased injected activity of
30 and 50%) regarding the large size of the lesions (10.6 and
13.0 cm, resp.), their necrotic character and the presence of
recently described, favorable predictive dosimetric parame-
ters (26). Twelve patients showed albumin macroaggregates
in their PVTT on the pretreatment technetium-99 macroag-
gregated albumin scanning (MAA SPECT/CT).
Tolerance was good for all patients. Adverse efects were
grade 3 or less on the CTCAEv3.0 scale. hree patients
(16.6%) complained of abdominal, three (16.6%) developed
asthenia, and one (5.5%) anorexia. Seven patients (38.9%)
developed transient liver dysfunction: 6 decompensations
with edema and ascite (including 1 with infection); 3 of the
6 were Child-Pugh B patients and 1 hepatic encephalopathy.
No deaths could be attributed to the treatment.
3.2. Response and Patient Survival Outcomes. Biological and
radiological response assessments were accomplished at 3, 6,
and 9 months for, respectively, 18, 17, and 14 patients.
Biological response was recorded in all 4 patients with
an elevated AFP level (>400 ng/mL) with an AFP decline of
more than 80%. Patients outcome are shown in Table 3.
he disease control rate was 83.3% with 2 complete
responses, 13 partial responses, and 1 stable disease. When
considering these 16 controlled patients, 13 showed objec-
tive radiologic response for both tumor and PVTT. Partial
patency of the portal vein was observed in eight patients and
complete involution of the thrombus in three others. For 15
of the 18 patients (83.3%), there was a change in the aspect of
the thrombus ater treatment: objective decrease in contrast
uptake due to devascularization of the portal tumor buds.
Among the twelve patients with albumin macroaggregates
deposit in their PVTT, nine showed patency of the portal
venous network. Two of them had complete involution of
their PVTT (Figure 1).
he two patients who received an intensiied treatment
showed a partial response without any signiicant toxicity.
Mean followup was 13.0 months (range 2.2–50.6). Fol-
lowup was less than 1 year for six patients; four of them
were dead. Survival rates at 6 months and 1 year were 88.5 ±
14.7% and 70.3 ± 21.1%, respectively. Median progression-
free survival was 11.0 months (in the treated liver) ater
treatment end (95% CI: 8.0–16.5). Median overall survival
was not reached (95% CI, 9.0–∞) (Figures 2 and 3). Seven
patients (38.8%) had died at study end; deaths occurred 2.2
to 15.7 months ater the irst treatment. Four of these seven
patients died because of the progression of the previously
treated disease.
At univariate analysis, there was a trend to signiicant
diference (� = 0.07) between controlled and noncontrolled
patients in term of median tumor absorbed dose (Table 2).
Downstaging allowed surgery in four patients (22%). Two
of them were downstaged to be within the transplantation
criteria [19]; one had a liver transplantation but the second
one refused it. hey, respectively, showed a progression free
survival and an overall survival of 50.6 and 50.6 and of
16.0 and 38.0 months. he two other patients did not meet
the transplantation criteria but were eligible for surgical
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Table 2: Treatment characteristics.
Characteristic Value
Selectivity of 90Y injection: whole liver/lobar/segmental 0/17/1
Median (range) activity (GBq) 2.5 (1.31–7.51)
Median (range) dose to the target volume (Gy) 117.8 (80.1–164.1)
Median (range) dose to the nontumoral liver (Gy) 75.5 (26.5–114.5)
Median (range) dose to the lungs (Gy) 3.8 (0–28.5)
Median (range) dose to the tumour (Gy) 261.1 (114.5–393.9)
Median (range) pulmonary shunt fraction (%) 2.4 (0–43.5)
Median (range) dose of controlled patients (complete response + partial response + stable disease) 284.5 (194.0–393.9)
Median (range) dose of nonresponders patients 181.5 (114.5–248.6)
Table 3: Treatment outcomes (� = 18).
Characteristics Value
Dead/alive (�) 7/11
Response (�) CR/PR/SD/PD 2/13/1/2
Objective response/disease control rate (%) 83.3/88.9%
Median (95% CI) time to progression
(months)
11.0 (8.0–16.5)
Median (95% CI) overall survival
(from date of treatment)
Not reached (9.0–∞)
Downstaging to surgery or transplantation
criteria (�) 4/18
Overall survival at 6 months (% and 95% CI) 88.5 ± 14.7
Overall survival at 1 year (% and 95% CI) 70.3 ± 21.1
resection. One had a right hepatectomy while the other
was discovered a second HCC during the surgery that con-
traindicated the programmed hepatectomy.hey respectively
showed a progression free survival and an overall survival of
13.8 and 14.8 and of 10.5 and 12.5 months.
4. Discussion
PVTT is a poor prognostic factor for HCC. According to the
BCLC classiication [4], patients with PVT have advanced-
stage disease, limiting options for surgery and intra-arterial
therapy. Systemic administration of sorafenib can yield sig-
niicant improvement in survival: median 8.1 months versus
4.9 with placebo for BCLC C patients with macrovascular
invasion [26]. Sorafenib cannot, however, be considered as a
curative treatment since there have been no reported cases of
downsizing. he objective response rate with sorafenib (such
as with other kinase inhibitors or monoclonal antibodies) is
very low, less than 3% with the RECIST criteria.
Selective internal radiation therapy was developed in the
1990s forHCCwith PVTT. 90Y is a higher energy beta emitter
(Beta max 2.2 versus 0.6MeV) with a broad cytoxicity range
[27]. Radiation protection is aminor problemwith 90Y, a pure
beta emitter, allowing day hospital protocols. High activity
doses may also be delivered to the tumor: median 2.5GBq
in our study with a maximum of 7.5GBq. he eicacy of
these selective internal radiation treatments has not been
assessed in prospective comparative trials (versus TACE, for
instance), but generally is considered comparable, with better
tolerance for radioembolization [28]. Data published to date
on the use of radioembolization for palliative purposes in
HCC patients with PVTT have demonstrated a very high
response rate (50–70%) [29], especially if the new response
criteria taking into account tumor vascularization are applied
[30]. he safety proile appears to be similar to that observed
in patients without PVTT, especially for the embolic risk.
his is also the case for resin microspheres: a recent series
had no cases of postembolization syndrome or of hepatic
ischemia [13]. he expression “selective internal radiation
therapy” should be preferred to the term “radioembolization”
since the embolic efect is marginal so that microspheres are
not to be contraindicated in patients with PVTT.
Our series conirmed the safety of this treatment, a fur-
ther argument favoring its eicacy on the thrombosis. Using
the EASL criteria, the tumor was controlled in 88.9% of our
patients at three months [19]; the thrombosis regressed in the
majority (11/18).his antitumor efect allowed downstaging to
surgery in four patients (22%). Pathology examination of the
explant in the patient who underwent liver transplantation
showed a major histological response in the tumor nodules
(the largest exhibited a totally necrotic aspect). he survival
rate (88.5% at six months) was promising, even better than
with sorafenib: mPFS = 11.0 in our series versus 4.1 months
in the subgroup with macrovascular invasion of the SHARP
trial [26]. Our results appear a little better than those
previously published (Table 4) probably because this cohort
is homogenous, containing only patients with lobar HCC and
intrahepatic ipsilateral PVTT whereas patients in previously
published studies showed indiferently lobar or bilobar HCC
and extended PVTT (extrahepatic or bilateral). hese results
are, however, in agreement with those just published in a
prospective phase 2 by Mazzaferro et al. [25] showing a
disease control rate of 74.3%, an mPFS of 7.0 (6.0–12.0), and
an mOS of 13.0 (9.0–17.0) months.
Like for some of these studies, our results conirm that
downstaging advanced HCC with PVTT is not an unrealistic
objective. Indeed, allowing to 22% (4/18) of these patients a
downstaging to a curative surgical stage is a very encouraging
data in the context of the classical poor outcome of this
disease. Concerning the 14 remaining patients, 11 showed
an objective response but unfortunately insuicient for a
secondary curative surgery (insuicient tumor size reduction
International Journal of Hepatology 5
(a) (b)
(c) (d)
Figure 1: MAA SPECT/CT and CT scans showing implantation of microspheres in an PVTT and the involution of this PVTT ater radi-
oembolization: (a) Baseline CT scan, (b) MAA SPECT/CT showing a high MAA uptake in the PVTT, (c) Posttherapeutic Bremsstrahlung
SPECT/CT ater the injection of 4.5GBq of 90Y-loaded glass microspheres: high uptake in the PVTT conirming the accurate implantation
of microspheres in the PVTT, and (d) CT scan at 13 months.
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Figure 2: Kaplan-Meier analysis of overall survival (months): medi-
an overall survival not reached (95%CI, 9.0–∞) aten mean follow-
up of 13.0 months.
and/or incomplete involution of the PVTT). Only 3 patients
did not respond to the treatment. For all 3, 90Y glass micros-
pheres were a front-line treatment and their median TD was
acceptable, higher than 114Gy. Two of these failures could
be explained by tumor sizes higher than 10 cm and the last
one could be due to an underlying advanced cirrhosis (Child-
Pugh B7), conditions known to be less favorable for SIRT.
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Figure 3: Kaplan-Meier analysis of progression-free survival
(months): median progression-free survival was 11.0 months (95%
CI: 8.0–16.5).
Our interesting results do not seem inluenced by the
27.7% (5/18) of patients previously treated. Indeed, even if
all these patients showed a partial response on their liver
tumor, 2 only of them showed partial patency of their portal
vein tumor thrombosis. On the contrary, all these 5 patients
showed adverse events (ascite), underscoring the risk of
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Table 4: Published studies on the treatment of HCC with PVTT with yttrium-90.
Study
(author/year/microspheres
type/reference)
PVTT
population/total
population
6-month
survival (%)
Disease Control rate at
�months (%)
Median OS
(months)
Median PFS
(months)
Salem et al., 2004: glass [15] � = 15/15 53 — 7.1
(4.1–13.9)
—
Woodall et al., 2009: glass
[18]
� = 15/52 — — 3.2 —
Kulik et al., 2008: glass [14] � = 37/108 — —
Branch
PVTT: 9.9 (7.1–15.7)
Main
PVTT: 4.4 (2.9–7.4)
—
Tsai et al., 2010: glass and
resin [17]
� = 22/22
15 evaluable
—
2-3 months : 58
(RECIST)
7.0 —
In˜arrairaegui et al., 2010:
resin
[13]
� = 25/25 64 2 months: 66.7 and
6 months: 50 (RECIST)
10.0
(6.6–13.3)
—
Hilgard et al., 2010: glass
[12]
� = 33/108
65
(95% CI
46–92%)
3 months: 90 (RECIST)
94 (EASL)
10.0 (6.0–∞) 8.0 (5.9–∞)
Salem et al., 2010: glass
[16]
� = 92/291
(35 Child A and 57
Child B)
—
2-3 months: 50 Child A
and 32 Child B (EASL)
10.4 (7.2–16.6) Child A
5.6 (4.5–6.7) Child B
5.6 (2.3–7.6) Child A
5.9 (4.2–7.9) Child B
Sangro et al., 2011: resin
[24]
� = 76/325
(branch + main)
— 3 months: 88.9% (EASL)
10.2
(7.7–11.8)
—
Mazzaferro et al., 2012: glass
[25]
� = 35/52
(branch + main)
— 3 months: 74.3 (EASL)
13.0
(9.0–17.0)
7.0
(6.0–12.0)
worse tolerance in case of pretreated tumors, especially ater
chemoembolization or large liver resections.
Regarding tumoral dosimetry, this study brings an inter-
esting result as controlled lesions had higher dosimetry with
a median dose to the tumor 284.5Gy (194–393.9). However,
the median tumor absorbed dose cannot in this small cohort
be hold as a predictive factor of tumor response despite a
trend to signiicance (� = 0.07) probably because a lack of
power. his point needs to be highlighted in the next future
as MAA SPECT/CT-based dosimetry results are available
ater the diagnostic angiography and before treatment and
we will further explore it by continuing publishing the data
of our patients showing lobar HCC with ipsilateral PVVT.
It seems that to achieve an objective response, a suicient
activity of 90Y-microspheres needs to be injected. his kind
of dose/response correlation has already been described by
Ho et al. in 1996 [22] in the classical partition model. In this
model, tumoral dosimetry (and tumoral activity) was eval-
uated using a tumor-to-nontumor uptake ratio evaluated by
SPECT and not a direct calculation of the tumoral activity as
we proposed here.he accuracy of this partitional model was
not optimal (37.5% of response if the tumoral dose was higher
than 225Gy and 10.3% if it was below this value) and tumoral
dosimetry has not yet been proposed for the treatment
planning (i.e., for the calculation of the activity to be injected).
Our results may change this point in the next future. Indeed,
we recently published preliminary results on 36HCCpatients
conirming this close dose response correlation [31]: a thresh-
old dose of 205Gy was predictive of the response with a sen-
sitivity of 100%, a speciicity of 66%, and an accuracy of 91%
(only 3 nonresponders above 205Gy on 36). Another conir-
mation has been brought by Chiesa et al. [32] who founded
a median dose of the responding lesion of 431 Gy as against
only 199Gy for the nonresponding lesion (� < 0.0001). he
tumoral dosimetry may now be shown not only as a part
of the treatment planning but also as a tool to optimize the
efectiveness of 90Y-microspheres radioembolization.
One of the major drawbacks of the present study is its
retrospective design and the lack of control group. Systemic
therapy with sorafenib was not started at the same time ater
90Y treatment in all patients who showed progressive disease,
and this may have inluenced overall survival. Finally, the
small number of patients did not allow the calculation
of signiicant diference in median tumor absorbed dose
between controlled and noncontrolled tumors.
Based on the results of the present study, it appears
that 90Y radioembolization in patients with unilobar HCC
and an ipsilateral intrahepatic PVTT conirmed the safety
and antitumor eicacy of this therapeutic option in this
population with an unfavorable prognosis with more than
20%of patients downstaged to a curative approach.Moreover,
this study hypothesized a predictive value of the MAA
SPECT/CT-based dosimetry on tumor response. Dosimetric
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optimizations could lead in the future to signiicant improve-
ments of 90Y radioembolization eicacy.
In light of our indings, a randomized trial would be
useful in this population to compare 90Y radioembolization
versus sorafenib alone. In addition to overall survival, the trial
should consider secondary curative surgery ater downsizing
as amain outcome criterion, similar to studies on livermetas-
tases from colorectal adenocarcinoma [33]. here should,
however, be some limits on inclusion: lobar HCC, ipsilateral
branch or intrahepatic trunk PVTT and an appropriate liver
function. Patients with bilateral thrombi or extension to the
extrahepatic trunk would be poor indications due to the
unfavorable beneit-risk ratio.
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